[1] Arana G，Rosenbaum J.Handbook of psychiatric drug therapy.4th edition.Philadelphia：Lippincott Williams & Wilkins，2000

[2] Alex KD，Pehek EA.Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Pharmacology & therapeutics，2007，113（2）：296-320

[3] la Fougère C，Meisenzahl E，Schmitt G，et al.D ₂ receptor occupancy during high- and lowdose therapy with the atypical antipsychotic amisulpride：a ¹²³I-iodobenzamide SPECT study.Journal of nuclear medicine：official publication，Society of Nuclear Medicine，2005，46（6）：1028-1033

[4] Tzimos A，Samokhvalov V，Kramer M，et al.Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia：a double-blind，placebocontrolled study with six-month open-label extension.The American journal of geriatric psychiatry：official journal of the American Association for Geriatric Psychiatry，2008，16（1）：31-43

[5] Suzuki T，Graff-Guerrero A，Uchida H，et al.Dopamine D _2/3 occupancy of ziprasidone across a day：a within-subject PET study.Psychopharmacology，2013，228（1）：43-51

[6] Takeuchi T，Furuta K，Hirasawa T，et al.Perospirone in the treatment of patients with delirium.Psychiatry and clinical neurosciences，2007，61（1）：67-70

[7] Citrome L.Lurasidone for schizophrenia：a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.International journal of clinical practice，2011，65（2）：189-210

[8] Ohoyama K，Tanii H，Motomura E，et al.Neuroleptic malignant syndrome induced by blonanserin.The Journal of neuropsychiatry and clinical neurosciences，2011，23（1）：E13

[9] Wang SM，Han C，Lee SJ，et al.Asenapine，blonanserin，iloperidone，lurasidone，and sertindole：distinctive clinical characteristics of 5 novel atypical antipsychotics.Clinical neuropharmacology，2013，36（6）：223-238

[10] Kane JM，Cohen M，Zhao J，et al.Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.Journal of clinical psychopharmacology，2010，30（2）：106-115

[11] Choi YK，Wong EH，Henry B，et al.Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors.International Journal of Neuropsychopharmacology，2010，13（3）：405-410

[12] Dargani NV，Malhotra AK.Safety profile of iloperidone in the treatment of schizophrenia.Expert opinion on drug safety，2014，13（2）：241-246

[13] Leucht S，Wahlbeck K，Hamann J，et al.New generation antipsychotics versus low-potency conventional antipsychotics：a systematic review and meta-analysis.Lancet，2003，361（9369）：1581-1589

[14] Mothi M，Sampson S.Pimozide for schizophrenia or related psychoses.Chichester：Cochrane database of systematic reviews，2013

[15] 江开达.精神药理学.第2版.北京：人民卫生出版社，2011

[16] Stahl SM.精神药理学精要：处方指南.第2版.于欣，司天梅，译.北京：北京大学医学出版社，2009